Cyxone recruits key members to the clinical development team
Cyxone today announced that the company has recruited Anna Polak and Levente Dajka as members of the Cyxone development team. Both will bring vast knowledge in clinical trial management, their initial focus will fall primarily on the preparations for the planned phase 2 trial investigating the clinical effect of Rabeximod in rheumatoid arthritis, set to start during 2021.
“I am delighted to welcome both Anna Polak and Levente Dajka to Cyxone as new members of our development team. They both bring a vast amount of experience from all stages of clinical drug development on a global scale. Their background in immunological diseases in general, and in multiple sclerosis and rheumatoid arthritis specifically, will be of great value as we increase our activities in preparing a regulatory submission to initiate the planned clinical phase 2 study in RA”, says Tara Heitner, CEO of Cyxone AB.Contact
Tara Heitner, CEO
Tel: +46 (0)70 781 88 08
This press release contains forward-looking statements that constitute subjective estimates and forecasts about the future. Assessments about the future are only valid on the date they are made and are, by their nature, similar to research and development work in the biotech field, associated with risk and uncertainty. In light of this, actual outcomes may differ substantially from what is described in this press release.About Cyxone
Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis as well as treatments for virally induced acute respiratory disorders. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis and moderate Covid-19 infections. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Certified Adviser is Mangold Fondkommission AB, +46 (0)8 503 015 50, firstname.lastname@example.org. For more information, please visit www.cyxone.comOpen Press release